HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $4.5.
April 01, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Unicycive Therapeutics with a maintained price target of $4.5.
The reiteration of a Buy rating and the maintenance of a $4.5 price target by a reputable analyst could positively influence investor sentiment towards UNCY, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100